MARKET

FSTX

FSTX

F-star Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.91
+0.04
+0.45%
Closed 19:35 03/02 EST
OPEN
9.03
PREV CLOSE
8.87
HIGH
9.44
LOW
8.86
VOLUME
41.36K
TURNOVER
--
52 WEEK HIGH
12.20
52 WEEK LOW
3.200
MARKET CAP
80.82M
P/E (TTM)
-1.3578
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DJ F-star Therapeutics Price Target Announced at $35.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
DJ F-star Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
Analysts Are Bullish on Top Healthcare Stocks: F-star Therapeutics (FSTX), Aerie Pharma (AERI)
SmarterAnalyst · 2d ago
--Analyst Actions: HC Wainwright & Co. Initiates Coverage on F-star Therapeutics at Buy Rating, Sets Price Target at $35
MT Newswires · 2d ago
The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 4)
Benzinga · 02/05 12:44
The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 3)
Benzinga · 02/04 12:21
Merck KGaA discloses 5.4% stake in F-star Therapeutics
F-star Therapeutics (FSTX) jumps 16% premarket after Merck KGaA (MKGAF) reports 5.4% passive stake in the company.Press Release
Seekingalpha · 02/02 10:05
F-Star secures European patent for FS118 in cancer
The European Patent Office ((EPO)) has granted F-star Therapeutics (FSTX) a patent with claims protecting the composition of matter of company's FS118 molecule throughout Europe.The expiry date of the patent
Seekingalpha · 01/20 14:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FSTX. Analyze the recent business situations of F-star Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FSTX stock price target is 22.67 with a high estimate of 35.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 66
Institutional Holdings: 5.24M
% Owned: 57.72%
Shares Outstanding: 9.07M
TypeInstitutionsShares
Increased
3
342.90K
New
12
642.28K
Decreased
11
290.68K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About FSTX
F-Star Therapeutics, Inc., formerly Spring Bank Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics for the treatment of viral infections, inflammatory diseases and cancers using its small molecule nucleotide platform. The Company is developing its product inarigivir soproxil (inarigivir), for the treatment of chronic hepatitis B virus (HBV). The Company's inarigivir selectively activates within infected hepatic cells the cellular protein, retinoic acid-inducible gene 1 (RIG-I), to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company also developing a second STING (STimulator of INterferon Genes) agonist product candidate, SB 11285, which is an immunotherapeutic agent for the potential treatment of selected cancers. The Company lead product is inarigivir.

Webull offers kinds of F-Star Therapeutics Inc stock information, including NASDAQ:FSTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FSTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FSTX stock methods without spending real money on the virtual paper trading platform.